TREATMENT GOALS FOR IDIOPATHIC PULMONARY FIBROSIS. A CLINICAL CASE

Abstract

Idiopathic pulmonary fibrosis is a chronic fibrosing interstitial pneumonia of unknown origin with a poor prognosis. Two antifibrotic drugs are used to treat this disease: pirfenidone and nintedanib, which can slow the decline in lung function and quality of life. Idiopathic pulmonary fibrosis is a chronic fibrosing interstitial pneumonia of unknown origin with a poor prognosis. Two anti-fibrotic drugs are used to treat this disease: pirfenidone and nintedanib, which can slow the decline in lung function and quality of life. A patient was diagnosed with idiopathic pulmonary fibrosis in 2013, based on clinical as well as typical histological and radiological signs characteristic of usual interstitial pneumonia. Since 2016, the patient has been treated with the antifibrotic drug nintedanib, which has significantly slowed the deterioration of lung function.